Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
26 09 2023
26 09 2023
Historique:
received:
19
07
2022
accepted:
02
06
2023
pmc-release:
26
09
2024
medline:
6
10
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Early treatment is associated with better long-term outcomes in patients with a first demyelinating event and early multiple sclerosis (MS). However, magnetic resonance (MR) findings are not usually integrated to construct propensity scores (PSs) when evaluating outcomes. We assessed the association of receiving very early treatment with the risk of long-term disability including an MR score (MRS) in patients with a first demyelinating event. We included 580 patients with a first demyelinating event prospectively collected between 1994 and 2021, who received at least 1 disease-modifying drug (DMD). Patients were classified into tertiles according to the cohort's distribution of the time from the first demyelinating event to the first DMD: first tertile (FT) or very early treatment (6 months; n = 194), second tertile (6.1-16 months, n = 192), and third tertile (TT) (16.1 months, n = 194). A 5-point MRS was built according to the sum of the following indicators: ≥9 brain lesions (1 point); ≥1 infratentorial lesion (1 point); ≥1 spinal cord (SC) lesion (1 point); ≥1 contrast-enhancing (CE) brain lesion (1 point); and ≥1 CE SC lesion (1 point). PS based on covariates and the MRS was computed for each of the outcomes. Inverse PS-weighted Cox and linear regression models assessed the risk of different outcomes between tertile groups. Finally, to confirm the role of MR in treatment decision, we studied the time elapsed from the first demyelinating event to treatment initiation according to the MRS in all patients with radiologic available information, renamed as raw-MRS. Very early treatment decreased the risk of reaching Expanded Disability Status Scale 3.0 (hazard ratio [HR] 0.55, 95% CI 0.32-0.97), secondary progressive MS (HR 0.40, 95% CI 0.19-0.85), and sustained disease progression at 12 months after treatment initiation (HR 0.50, 95% CI 0.29-0.84), when compared with patients from the TT group. Patients from the FT group had a lower disability progression rate (β estimate -0.009, 95% CI -0.016 to -0.002) and a lower severe disability measured by the Patient-Determined Disease Step (β estimate -0.52, 95% CI -0.91 to -0.13) than the TT group. Finally, there was a 62.4% reduction in the median time between the first demyelinating event and the first-ever treatment initiation from patients displaying a raw-MRS 1 to patients with a raw-MRS 5. Using PS models with and without MRS, we showed that treatment initiation at very early stages is associated with a reduction in the risk of long-term disability accrual in patients with a first demyelinating event. This study provides Class III evidence that earlier treatment of patients with MS presenting with a first demyelinating event is associated with improved clinical outcomes.
Sections du résumé
BACKGROUND AND OBJECTIVES
Early treatment is associated with better long-term outcomes in patients with a first demyelinating event and early multiple sclerosis (MS). However, magnetic resonance (MR) findings are not usually integrated to construct propensity scores (PSs) when evaluating outcomes. We assessed the association of receiving very early treatment with the risk of long-term disability including an MR score (MRS) in patients with a first demyelinating event.
METHODS
We included 580 patients with a first demyelinating event prospectively collected between 1994 and 2021, who received at least 1 disease-modifying drug (DMD). Patients were classified into tertiles according to the cohort's distribution of the time from the first demyelinating event to the first DMD: first tertile (FT) or very early treatment (6 months; n = 194), second tertile (6.1-16 months, n = 192), and third tertile (TT) (16.1 months, n = 194). A 5-point MRS was built according to the sum of the following indicators: ≥9 brain lesions (1 point); ≥1 infratentorial lesion (1 point); ≥1 spinal cord (SC) lesion (1 point); ≥1 contrast-enhancing (CE) brain lesion (1 point); and ≥1 CE SC lesion (1 point). PS based on covariates and the MRS was computed for each of the outcomes. Inverse PS-weighted Cox and linear regression models assessed the risk of different outcomes between tertile groups. Finally, to confirm the role of MR in treatment decision, we studied the time elapsed from the first demyelinating event to treatment initiation according to the MRS in all patients with radiologic available information, renamed as raw-MRS.
RESULTS
Very early treatment decreased the risk of reaching Expanded Disability Status Scale 3.0 (hazard ratio [HR] 0.55, 95% CI 0.32-0.97), secondary progressive MS (HR 0.40, 95% CI 0.19-0.85), and sustained disease progression at 12 months after treatment initiation (HR 0.50, 95% CI 0.29-0.84), when compared with patients from the TT group. Patients from the FT group had a lower disability progression rate (β estimate -0.009, 95% CI -0.016 to -0.002) and a lower severe disability measured by the Patient-Determined Disease Step (β estimate -0.52, 95% CI -0.91 to -0.13) than the TT group. Finally, there was a 62.4% reduction in the median time between the first demyelinating event and the first-ever treatment initiation from patients displaying a raw-MRS 1 to patients with a raw-MRS 5.
DISCUSSION
Using PS models with and without MRS, we showed that treatment initiation at very early stages is associated with a reduction in the risk of long-term disability accrual in patients with a first demyelinating event.
CLASSIFICATION OF EVIDENCE
This study provides Class III evidence that earlier treatment of patients with MS presenting with a first demyelinating event is associated with improved clinical outcomes.
Identifiants
pubmed: 37468284
pii: WNL.0000000000207664
doi: 10.1212/WNL.0000000000207664
pmc: PMC10558169
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1280-e1292Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 American Academy of Neurology.
Références
Mult Scler. 2016 May;22(6):830-41
pubmed: 26238464
J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285-294
pubmed: 28039317
J Am Coll Cardiol. 2017 Jan 24;69(3):345-357
pubmed: 28104076
Lancet Neurol. 2020 Apr;19(4):307-316
pubmed: 32199096
Neurology. 2021 Feb 2;96(5):e783-e797
pubmed: 33372028
Mult Scler. 2017 Aug;23(9):1233-1240
pubmed: 27754943
Ann Neurol. 2016 Oct;80(4):499-510
pubmed: 27464262
JAMA Neurol. 2020 Sep 1;77(9):1132-1140
pubmed: 32511687
Eur J Neurol. 2018 Oct;25(10):1262-e110
pubmed: 29847005
Lancet Neurol. 2015 May;14(5):497-505
pubmed: 25841667
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):251-260
pubmed: 30242090
Neurology. 2012 Jun 5;78(23):1860-7
pubmed: 22573626
BMC Neurol. 2013 Apr 25;13:37
pubmed: 23617555
Neurology. 2022 Jan 4;98(1):e1-e14
pubmed: 34716250
Mult Scler Relat Disord. 2022 Mar;59:103644
pubmed: 35182881
JAMA Neurol. 2019 May 1;76(5):536-541
pubmed: 30776055
Mult Scler. 2013 Jul;19(8):1074-83
pubmed: 23234810
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Lancet. 2009 Oct 31;374(9700):1503-11
pubmed: 19815268
Brain. 2022 Sep 14;145(9):3147-3161
pubmed: 35104840
Ann Neurol. 2009 Oct;66(4):513-20
pubmed: 19847899
Lancet Neurol. 2014 Mar;13(3):257-67
pubmed: 24502830
Brain. 2020 Sep 1;143(9):2742-2756
pubmed: 32947619
Lancet Neurol. 2021 Aug;20(8):653-670
pubmed: 34139157
Neurology. 2021 Oct 26;97(17):e1641-e1652
pubmed: 34521693
Mult Scler Relat Disord. 2019 Aug;33:131-138
pubmed: 31195337
Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S65-9
pubmed: 24321159
Mult Scler. 2015 Apr;21(4):433-41
pubmed: 25257611
Mult Scler. 2018 Feb;24(2):96-120
pubmed: 29353550
Lancet. 2007 Aug 4;370(9585):389-97
pubmed: 17679016
Mult Scler. 2012 Nov;18(11):1617-24
pubmed: 22653659
JAMA. 2019 Jan 15;321(2):175-187
pubmed: 30644981
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9
pubmed: 24218527
Eur J Neurol. 2022 May 26;:
pubmed: 35617144
Brain. 2015 Jul;138(Pt 7):1863-74
pubmed: 25902415
Mult Scler. 2021 Sep;27(10):1543-1555
pubmed: 33900144
Ann Neurol. 2016 Jul;80(1):89-100
pubmed: 27145331
Neurology. 2016 Sep 06;87(10):978-87
pubmed: 27511182
Arch Neurol. 2012 Feb;69(2):183-90
pubmed: 21987393
Neurology. 2020 Aug 25;95(8):e1041-e1051
pubmed: 32636328
Stat Med. 2016 Dec 30;35(30):5642-5655
pubmed: 27549016
Lancet Neurol. 2014 Oct;13(10):977-86
pubmed: 25192851
N Engl J Med. 2000 Sep 28;343(13):898-904
pubmed: 11006365
Lancet Neurol. 2012 Jan;11(1):33-41
pubmed: 22146409